MEMRI in Ischaemic, Inflammatory and Takotsubo Cardiomyopathy (MEMORY)
Research type
Research Study
Full title
Manganese- Enhanced Magnetic Resonance Imaging (MEMRI) in Ischaemic, Inflammatory and Takotsubo Cardiomyopthy (MEMORY)
IRAS ID
271643
Contact name
David Newby
Contact email
Sponsor organisation
University of Edinburgh
Duration of Study in the UK
2 years, 3 months, 1 days
Research summary
Scanning the heart using magnetic resonance imaging (MRI) enables detailed assessment of its structure and function. MRI can give more detailed information about the heart by using a contrast ‘dye' that is injected into a vein during the scan. This can highlight abnormal areas within the heart. Current contrast dyes help identify scarring within the heart. Recent studies using a new contrast dye containing manganese has shown advantages over traditional contrast. We plan to further test this manganese containing dye as we believe it will provide insight in other cardiac conditions.
There are many causes of heart problems and we plan to use this new contrast agent to scan three patient groups;
heart artery disease (coronary heart disease), (b) and inflamed heart (myocarditis), or (c) broken-heart syndrome (takotsubo cardiomyopathy). We will scan healthy volunteers for comparison.
The study will be carried out at the Royal Infirmary of Edinburgh. Adults between 18 and 65 with stable heart failure can be considered. Women who may be pregnant are unable to participate, as is anyone who has some types of metal in their body, as these people can’t have an MRI scan safely. All participants in clinical cohorts will have 2 MRI scans lasting about an hour each, at least 2 days apart. Some participants will be have 3 MRI scans, over a longer time period. Healthy volunteers will have 1 MRI scan only. We will also take some blood samples and record a tracing of the heart rhythm. We will ensure there are no abnormal side-effects by telephone follow up.
We believe this new agent has potential to better measure disease in the heart, improve our ability to establish the cause of heart disease and help monitor the disease over time as well as guide future treatment for individual patients.REC name
South East Scotland REC 01
REC reference
20/SS/0001
Date of REC Opinion
20 Dec 2019
REC opinion
Further Information Favourable Opinion